Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury

Arthur Lau, … , Craig N. Jenne, Daniel A. Muruve


Radiographic contrast agents cause acute kidney injury (AKI), yet the underlying pathogenesis is poorly understood. Nod-like receptor pyrin containing 3–deficient (Nlrp3-deficient) mice displayed reduced epithelial cell injury and inflammation in the kidney in a model of contrast-induced AKI (CI-AKI). Unexpectedly, contrast agents directly induced tubular epithelial cell death in vitro that was not dependent on Nlrp3. Rather, contrast agents activated the canonical Nlrp3 inflammasome in macrophages. Intravital microscopy revealed diatrizoate (DTA) uptake within minutes in perivascular CX3CR1+ resident phagocytes in the kidney. Following rapid filtration into the tubular luminal space, DTA was reabsorbed and concentrated in tubular epithelial cells via the brush border enzyme dipeptidase-1 in volume-depleted but not euvolemic mice. LysM-GFP+ macrophages recruited to the kidney interstitial space ingested contrast material transported from the urine via direct interactions with tubules. CI-AKI was dependent on resident renal phagocytes, IL-1, leukocyte recruitment, and dipeptidase-1. Levels of the inflammasome-related urinary biomarkers IL-18 and caspase-1 were increased immediately following contrast administration in patients undergoing coronary angiography, consistent with the acute renal effects observed in mice. Taken together, these data show that CI-AKI is a multistep process that involves immune surveillance by resident and infiltrating renal phagocytes, Nlrp3-dependent inflammation, and the tubular reabsorption of contrast via dipeptidase-1.

Find the latest version:

http://jci.me/96640/pdf
Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury

Arthur Lau,1,2 Hyunjae Chung,1,2 Takanori Komada,1,2 Jaye M. Platnich,1,2 Christina F. Sandall,3,4 Paul R. Roy Choudhury,5,6 Justin Chum,1,2 Victor Naumenko,2,7 Bas G.J. Surewaard,2,7 Michelle C. Nelson,1,2 Annegret Ulke-Lemée,3,4 Paul L. Beck,1,2 Halgrimur Benediktsson,2,8 Anthony M. Jevnikar,9 Sarah L. Snelgrove,10 Michael J. Hickey,10 Donna L. Senger,5,6 Matthew T. James,1,4 Justin A. Macdonald,3,4 Paul Kubes,2,7 Craig N. Jenne,2,7 and Daniel A. Muruve1,2

1Department of Medicine, 5Snyder Institute for Chronic Diseases, 6Department of Biochemistry and Molecular Biology, 7Libin Cardiovascular Institute of Alberta, 8Department of Oncology, 9Arnie Charbonneau Cancer Institute, 10Department of Microbiology, Immunology, and Infectious Diseases, and 9Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada. 10Department of Medicine, University of Western Ontario, London, Ontario, Canada. 11Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Clayton, Victoria, Australia.

Radiographic contrast agents cause acute kidney injury (AKI), yet the underlying pathogenesis is poorly understood. NOD-like receptor pyrin containing 3-deficient (NLrP3-deficient) mice displayed reduced epithelial cell injury and inflammation in the kidney in a model of contrast-induced AKI (CI-AKI). Unexpectedly, contrast agents directly induced tubular epithelial cell death in vitro that was not dependent on NLrP3. Rather, contrast agents activated the canonical NLrP3 inflammasome in macrophages. Intravital microscopy revealed diatrizoate (DTA) uptake within minutes in perivascular CX3CR1-expressing resident macrophages in the kidney. Following rapid filtration into the tubular luminal space, DTA was reabsorbed and concentrated in tubular epithelial cells via the brush border enzyme dipeptidase-1 in volume-depleted but not euolemic mice. LysM-GFP+ macrophages recruited to the kidney interstitial space ingested contrast material transported from the urine via direct interactions with tubules. CI-AKI was dependent on resident renal phagocytes, IL-1, leukocyte recruitment, and dipeptidase-1. Levels of the inflammasome-related urinary biomarkers IL-18 and caspase-1 were increased immediately following contrast administration in patients undergoing coronary angiography, consistent with the acute renal effects observed in mice. Taken together, these data show that CI-AKI is a multistep process that involves immune surveillance by resident and infiltrating renal phagocytes, NLrP3-dependent inflammation, and the tubular reabsorption of contrast via dipeptidase-1.

Introduction
Contrast-induced acute kidney injury (CI-AKI) is caused by iotinated contrast media for diagnostic imaging (1). Most patients with normal kidney function who receive contrast will not experience any renal complications; however, those with volume depletion or chronic kidney disease (CKD) are at increased risk for CI-AKI (2–4). CI-AKI occurs within 24–72 hours following the administration of radiographic contrast agents and is associated with adverse outcomes including acute renal failure requiring dialysis, worsening of CKD, cardiovascular events, and increased health care costs (2). Although numerous clinical and epidemiological studies have characterized the risk factors and incidence rates of CI-AKI in stratified patient populations, the underlying pathogenesis of CI-AKI is poorly understood (1, 5).

Contrast agents are known to induce a variety of alterations in the kidney that include medullary ischemia, formation of reactive oxygen species, and tubular cell toxicity (1); however, the exact mechanism of tissue injury, and specifically the role of inflammation, has not been clearly characterized. The incomplete understanding of CI-AKI has hampered the development of new therapeutic strategies to prevent or minimize CI-AKI.

Inflammation is an integral component of acute and CKDs. Leukocytes play important roles in kidney parenchymal injury, repair, and fibrosis (6, 7). The kidney contains an intrinsic immune surveillance system that consists of resident macrophages and dendritic cells (herein referred to as resident renal phagocytes) expressing a series of overlapping markers such as CD11b, CD11c, F4/80, and CX3CR1 (8). The current understanding of the intrarenal immune system in kidney disease remains limited and is inferred primarily from cell depletion studies (7). While kidney-resident renal phagocytes contribute to the pathogenesis of kidney disease, the respective temporal behaviors, cell-cell interactions, and specific role of various leukocyte populations in renal pathophysiology are not fully characterized. Furthermore, the additional contribution of leukocyte populations recruited from the systemic circulation in propagating kidney injury and inflammation requires ongoing clarification.

Related Commentary: p. 2754
The Journal of Clinical Investigation

RESEARCH ARTICLE

Canonical and noncanonical roles in models of kidney disease (11–15). The canonical Nlrp3 inflammasome is a platform for caspase-1 activation that regulates the maturation of IL-1β and IL-18. Studies from our laboratory show that within the epithelial cell compartment of the kidney, Nlrp3 function is primarily noncanonical, regulating a platform for caspase-8 activation and apoptotic cell death rather than caspase-1 and cytokine maturation (11). Thus, the canonical Nlrp3 inflammasome likely resides primarily within resident renal phagocytes or circulating leukocytes recruited to the injured kidney (16).

In this study, we show that CI-AKI is a multistep process involving immune activation coordinated by resident renal phagocytes, the tubular reabsorption of contrast media, and recruited leuko-
**A**

Nlrp3$^{+/+}$

Nlrp3$^{-/-}$

Vehicle  |  6 h  |  d 1  |  d 3
---      |      |      |      

**B**

Adherent GFP$^+$ cells/field

- **Nlrp3$^{+/+}$**
- **Nlrp3$^{-/-}$**

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>6 h</th>
<th>d 1</th>
<th>d 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nlrp3$^{+/+}$</strong></td>
<td></td>
<td><strong>250</strong></td>
<td><strong>200</strong></td>
<td><strong>150</strong></td>
</tr>
<tr>
<td><strong>Nlrp3$^{-/-}$</strong></td>
<td></td>
<td></td>
<td><strong>100</strong></td>
<td><strong>50</strong></td>
</tr>
</tbody>
</table>

**C**

IVRS

**D**

% LysM$^+$ cells

- **LysoM$^{+/+}$CD11b$^+$Ly6G$^+$** (neutrophils)
- **LysoM$^{+/+}$CD11b$^+$Ly6C$^+$** (monocytes)

<table>
<thead>
<tr>
<th></th>
<th>Nlrp3$^{+/+}$</th>
<th>Nlrp3$^{-/-}$</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vehicle</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IVRS</td>
<td><strong>35</strong></td>
<td><strong>10</strong></td>
</tr>
</tbody>
</table>

**E**

F4/80

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>IVRS d 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nlrp3$^{+/+}$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nlrp3$^{-/-}$</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**F**

F4/80 expression (fold change)

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>d 3 IVRS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nlrp3$^{+/+}$</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nlrp3$^{-/-}$</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
cytes, tubular cells, and recruited leukocytes in kidney injury and the understanding of the interplay among resident renal phagocytes. The brush border enzyme dipeptidase-1 (DPEP-1), another key component of inflammation rather than via direct Nlrp3-mediated tubular cell injury, was not observed in Nlrp3–/– mice, consistent with the overall decrease in inflammation and AKI in this strain.

Tubular cell injury increased in Nlrp3+/+ mice. Our studies and others have demonstrated the direct cytotoxic effect of contrast media on renal TECs (12–15). To disect the role of Nlrp3 in CI-AKI, we administered the non-ionic low-osmolar contrast agent ioversol, and cell viability was examined. Not surprisingly, the two contrast agents were equally capable of inducing contrast-induced epithelial cell toxicity. Cell death above experimental conditions controlling for osmolar properties that are toxic to epithelial cells.

**Results**

*Contrast-induced epithelial cell toxicity does not require Nlrp3.*

Numerous studies have demonstrated the direct cytotoxic effect of contrast media on renal TECs (1, 18, 19). Primary human proximal TECs (HTCs) were treated with ioversol or the ionic contrast agent diatrizoate (DTA), and cell viability was examined. Not surprisingly, the two contrast agents were equally capable of inducing cell death in HTCs within 24 hours as determined by MTT assay (Figure 3C and Suplemental Figure 2A). The cytotoxic effects of contrast agents diminished with dilution that would be expected to occur in most clinical scenarios, such as in patients receiving i.v. contrast. Importantly, there are significant confounding variables in the in vitro assay due to superphysiologic osmotic load and the dilution of nutrients caused by the addition of contrast agents to cell culture media. Cell viability was also substantially reduced in control experiments using equivalent volumes of PBS (Supplemental Figure 2B). However, cell death above experimental conditions controlling for osmolality or nutrient deficiency confirmed that ioversol exhibits inherent properties that are toxic to epithelial cells.
Contrast activates the canonical Nlrp3 inflammasome in macrophages. The preceding studies suggested that the role of Nlrp3 in CI-AKI may require the canonical inflammasome as opposed to directing epithelial cell death. Ioversol induced caspase-1 activation and IL-1β cleavage in THP-1 macrophages as detected by immunoblotting (Figure 4A). The ionic contrast agent DTA also induced IL-1β secretion in macrophages at 6 hours (Figure 4B). Confocal microscopy confirmed the formation of caspase-1–positive ASC specks at 6 hours following ioversol stimulation, indicative of active inflammasomes (Figure 4C). To confirm that inflammasome activation by contrast agents was mediated by Nlrp3, we deleted Nlrp3 expression in THP-1 macrophages using CRISPR-Cas9 gene editing. The absence of Nlrp3 completely abrogated ioversol-induced IL-1β activation, an effect that was also observed in mouse Nlrp3−/− bone marrow–derived macrophages (BMDMs) (Figure 4, D and E). Consistent with these data, WT mice receiving ioversol expressed higher levels of renal IL-1β at 6 hours in vivo compared with Nlrp3−/− animals (Figure 4F). Bone marrow chimera studies demonstrated that most of IL-1β production in vivo was dependent on hematopoietic cells (leukocytes), since IL-1β levels were significantly increased in Nlrp3−/− mice receiving Nlrp3+/− bone marrow, compared with Nlrp3−/− mice receiving Nlrp3+/− cells (Figure 4G). Consistent with this result, there was no evidence of ioversol-induced inflammasome activation (caspase-1 cleavage or IL-1β production) in mouse primary kidney pericytes or human glomerular endothelial cells.
lial cells (Supplemental Figure 5), supporting the notion that the majority of inflammasome activity induced by contrast in the kidney originates from the leukocytes.

To explore further the mechanism of inflammasome activation by contrast agents, we tested the contribution of damage-associated molecular patterns (DAMPs) released from ioversol-injured epithelial cells, since canonical inflammasome activation by radiographic contrast in leukocytes in vivo could be induced either directly by contrast or indirectly in response to contrast-mediated tubular injury. Both ioversol and DAMPs released from ioversol-injured HPTCs alone were sufficient to induce IL-1β release from THP-1 macrophages (Figure 4H). The combination of HPTC DAMPs and ioversol, however, was not additive or synergistic, as IL-1β secretion increased only marginally compared with either stimulation alone. Finally, canonical inflammasome activation by ioversol was not affected by the RIP-1 inhibitor necrostatin-1, which has been previously shown to attenuate CI-AKI in vivo (ref. 19 and Supplemental Figure 6). Taken together, these data show that contrast induces the canonical Nlrp3 inflammasome primarily in leukocytes in vitro and in vivo.

Resident renal phagocytes and recruited leukocytes provide vascular and urinary immune surveillance in the kidney. Inflammation plays a significant role in the pathogenesis of multiple kidney diseases (7, 15); however, the mechanism underlying the initiation and propagation of an inflammatory response in kidney injury remains incompletely understood. Recent studies have shown that perivascular resident renal phagocytes play a key role in the immune surveillance of immune complexes in the circulation (9, 10). To further probe the mechanism of Nlrp3 inflammasome activation and the subsequent immune response triggered by contrast in vivo, we labeled DTA on its free carboxyl group with CF568 (CF568-DTA) to visualize the temporal handling of contrast in the kidney using intravital microscopy (ioversol is non-ionic, and labeling with CF568 was therefore not possible). In prehydrated LysM(gfp/gfp) mice, contrast rapidly entered the peritubular capillary network, emerging quickly into the tubular lumen, and cleared within 5 minutes (Figure 5A and Supplemental Video 4). The entry into the tubular lumen likely occurred via glomerular filtration, as no direct transit of contrast from the vascular space to the tubulointerstitial compartment was observed. Consequently, in prehydrated LysM(gfp/gfp) mice, no leukocyte recruitment was seen. Interestingly, in prehydrated CX3CR1(gfp/+), LysM(gfp/gfp) mice, significant uptake of CF568-DTA was detected in resident CX3CR1+ renal phagocytes within 30 seconds, confirming a potential mechanism to activate the Nlrp3 inflammasome in these cells (Figure 5B). Next CF568-DTA was administered to volume-depleted mice. As in prehydrated mice, CF568-DTA rapidly appeared in the peritubular capillary network, followed by entry into the tubular lumen likely by glomerular filtration (Figure 5, A and C, and Supplemental Video 5). Rapid contrast uptake into CX3CR1+ resident renal phagocytes was also observed by microscopy and confirmed by flow cytometry to include CX3CR1+ and CD11c+ cells (Figure 5, D and E, and Supplemental Video 6). Compared with the prehydrated state, CF568-DTA was reabsorbed, accumulated, and retained in tubules in a patchy manner over 40 minutes (Figure 5, A and C, and Supplemental Videos 5 and 7). The amount of contrast accumulating in the tubules, however, constituted a small fraction of the total administered contrast, since the majority was seen in the bladder of the mice at 1 hour by x-ray imaging (Supplemental Figure 7). In volume-depleted LysM(gfp/gfp) mice, the recruitment of GFP+ leukocytes coincided with contrast accumulation in renal tubules (Figure 5A, Figure 6A, and Supplemental Figure 8A). Intravital microscopy over 60 minutes revealed an increased number of crawling of GFP+ leukocytes in the interstitial space along contrast-laden tubules, as well as migration into the tubular epithelial layer and tubular lumen (Figure 6B and Supplemental Video 8). Direct interactions between GFP+ leukocytes and tubular cells were observed, with GFP+ leukocytes actively taking up contrast material, detaching from the tubule, and migrating away from the field (Figure 6B and Supplemental Video 8). Unlike LysM-GFP+ leukocyte migration and movement in the kidneys around contrast-laden tubules, CX3CR1+ dendritic cells showed little to no movement or change in position, extension, or retraction activity (Supplemental Figure 8B). Furthermore, similar uptake of filtered contrast from tubules to CX3CR1+ resident renal phagocytes was not observed (Supplemental Video 6), suggesting that this property was exclusive to the recruited leukocyte population. CD45+CF568-DTA+ leukocytes isolated from WT kidneys were analyzed by flow cytometry and found to be primarily Ly6C+ /F4/80– but largely Ly6G+/F4/80+, consistent with contrast uptake by recruited monocytes/macrophages (Figure 6C and Figure 7). Only a small population of CD45+CD11b+Ly6G–/Ly6C+ neutrophils was present in the kidney 1 hour after contrast administration, and very few of these cells were CF568-DTA+ (Figure 6C). Control experiments using CF568 alone or a mock preparation of CF658-acetate in volume-depleted mice demonstrated no tubular accumulation or inflammatory response, confirming that the effects seen were dependent on the DTA contrast agent (Supplemental Figure 9). Contrast uptake by recruited monocytes/macrophages was dependent on ICAM-1, a leukocyte adhesion molecule. In mice pretreated with blocking anti–ICAM-1 antibody, a reduction in recruited CD11b+CX3CR1+Ly6C+ /F4/80– cells was observed in response to CF568-DTA at 1 hour. Furthermore, in the remaining kidney monocytes/macrophages, the proportion of CF568-DTA+ cells was reduced compared with that in IgG control–treated mice (Figure 7). Uptake of contrast by monocytes/macrophages was not dependent on scavenger receptor A (SR-A), since the apolipoprotein-A1 mimetic and SR-A binding peptide D-4F (21, 22) had minimal effect on the proportion of recruited monocytes/macrophages taking up DTA (Figure 7). Of note, leukocyte uptake of CF568-DTA was not detectable in mice at 6 hours, likely due to clearance of the fluorescent contrast reagent from the kidney (Supplemental Figure 10). Thus, during CI-AKI, early immune surveillance occurs from both resident renal phagocytes and recruited monocytes/macrophages. Resident renal phagocytes sample contrast from the circulation, while recruited monocytes/macrophages take up contrast transported from the urine through direct interaction with tubular cells.

Contrast activates the inflammasome in resident renal phagocytes and infiltrating monocytes/macrophages. The previous experiments demonstrated that radiographic contrast activates the inflammasome in macrophages in vitro and that resident and infiltrating macrophages take up contrast in vivo. Flow cytometry was used to demonstrate inflammasome activation in these cell populations in vivo (Figure 8). At 6 hours following ioversol administration to WT mice, an increase in CD11b+CX3CR1Ly6C+ /F4/80–CCR2+ and CD11b+CX3CR1Ly6G–/F4/80–CCR2+ monocytes/macrophages was
Nlrp3–/– inflammasome in response to contrast and other DAMPs (Supplemental Figure 11A). Consistent with this finding, renal function and serum creatinine were improved in Ly6G-depleted mice (Figure 9A and B). Similar results were obtained when leukocyte recruitment was inhibited using blocking ICAM-1 antibodies (Figure 7 and Supplemental Figure 13A). Next, experiments were performed using clodronate-liposomes, which deplete resident renal phagocytes and some systemic macrophage populations (7). Clodronate-liposomes were administered to LysM<sup>gfp/gfp</sup> mice, and the population of resident renal phagocytes was confirmed depleted by F4/80 staining and flow cytometry (Figure 9C and Supplemental Figure 13B). In clodronate-liposome–treated mice, macrophage depletion was associated with reduced GFP⁺ leukocyte recruitment at 6 hours and improved kidney function at 3 days (Figure 9, C and D). These results were consistent with findings in diphtheria toxin–treated (DT-treated) CD11c-DTR transgenic mice (23). Since more than 90% of resident renal phagocytes express CD11c (8), DT treatment in this strain eliminates the majority of resident cells. Like clodronate-liposome–treated mice, CD11c-depleted animals displayed less early inflammation, confirming that resident renal phagocytes are necessary for leukocyte recruitment during CI-AKI (Supplemental Figure 13, C and D).

Finally, to determine whether IL-1β played a significant role in mediating leukocyte recruitment during contrast administration, we pretreated LysM<sup>gfp/gfp</sup> mice with the soluble IL-1 receptor antagonist IL-1Ra prior to contrast administration. Consistent with the prior data, IL-1Ra diminished GFP⁺ leukocyte recruitment to the kidney at 6 hours, which translated into better renal function and serum creatinine at 3 days (Figure 9, E and F). KIM-1 expression and F4/80⁺ macrophage infiltration in the kidney was also reduced in IL-1Ra–treated mice at 3 days (Supplemental Figure 14). In summary, the resident renal phagocytes ICAM-1 and IL-1 regulate contrast-induced leukocyte recruitment to the kidney that is necessary for CI-AKI.

Resident DPEP-1 mediates tubular uptake of contrast in the urine. DPEP-1 is a glycosyl phosphatidylinositol-anchored (GPI-anchored) renal proximal tubule brush border enzyme that regulates the tubular uptake of imipenem as well as other tubular toxins, such as cisplatin, vancomycin, cyclosporine, and aminoglycosides (24–26). These studies suggest that DPEP-1 may function as a luminal receptor for a variety of molecules or drugs entering the urine following glomerular filtration. To determine whether DPEP-1 also regulates uptake of contrast into cells, we performed in vitro studies in primary HPTCs and DPEP-1–negative COS-1 cells transfected with human DPEP-1 (Figure 10, A and B, and Supplemental Figure 15, B and C). HPTCs expressed abundant DPEP-1 that was effectively deglycosylated using the endoglycosidase peptide/N-glycosidase F (PNGaseF) to impair DPEP-1 apical targeting and activity (ref. 27, Figure 10A, and Supplemental Figure 15A). HPTCs and DPEP-1–transfected COS cells internalized CF568-labeled DTA as detected by fluorescence live cell imaging, effects that were absent in PNGaseF-treated HPTCs and nontransfected COS cells (Figure 10, A and B, and Supplemental Figure 15, B–D). To test whether DPEP-1 mediated tubular uptake of contrast in vivo, we pretreated volume-depleted WT mice with the DPEP-1–specific inhibitor cilastatin prior to the administration of CF568-DTA and monitored them by intravital microscopy. Compared with control, cilastatin prevented tubular uptake of contrast in vivo.
Inflammasome-related biomarkers are detected in humans undergoing coronary angiography. The previous results demonstrated early activation of the Nlrp3 inflammasome and inflammation in a mouse model of CI-AKI. To determine whether inflammasome activation could also be detected in humans receiving arterial contrast, we evaluated urine biomarkers in patients drawn from a prospective study of CI-AKI following coronary angiography. Forty-two stable patients undergoing elective coronary angiography were selected randomly from this cohort and their urine samples analyzed for inflammation biomarkers using the Meso Scale Discovery assay. Although patients in this study are being followed for AKI and CKD long-term,
after angiogram, whereas 4 patients with no leukocyturia did not show evidence of urinary caspase-1 (Figure 11D). In general, the presence of urinary caspase-1 was associated with positive urine leukocytes by urinalysis (Figure 11E), consistent with the mouse data and the hypothesis that inflammasome activation by contrast occurs primarily in leukocytes. IL-1β was detectable at very low concentrations in the patient urine samples; however, a significant increase after contrast administration could not be detected. Similarly, multiple other biomarkers including IL-6, lipocalin-2 (NGAL), MCP-1, EGF, and IL-1α, were not significantly increased in patient urine immediately after contrast administration (data not shown). Finally, none of the biomarkers were predictive of AKI within 7 days. In a preliminary analysis, the incidence of CI-AKI in this stable patient cohort was low and less than 10%, consistent with the multiple factors, aside from inflammation, needed to develop this clinical complication.

urine samples were collected and analyzed before and immediately after angiogram (<24 hours), before the onset of clinical AKI. All patients met the inclusion criteria of an estimated glomerular filtration rate (GFR) of less than 60 ml/min/1.73 m² (CKD Epidemiology Collaboration [CKD-EPI] equation); patient characteristics are presented in Supplemental Table 1. The administration of arterial contrast significantly increased urinary expression of the inflammasome-dependent cytokine IL-18 as well as the tubular injury marker KIM-1 (Figure 11, A and B). In 4 of 8 randomly chosen patients from this cohort, cleaved caspase-1 could be detected in the urine pellets after contrast administration (Figure 11C). To assess whether urinary caspase-1 was associated with the presence of leukocytes in the urine, we selected an additional 9 patients based on the presence or absence of leukocyturia by urinalysis. In 5 patients, detectable urinary caspase-1 correlated with an increase in urine leukocytes after angiogram, whereas 4 patients with no leukocyturia did not show evidence of urinary caspase-1 (Figure 11D). In general, the presence of urinary caspase-1 was associated with positive urine leukocytes by urinalysis (Figure 11E), consistent with the mouse data and the hypothesis that inflammasome activation by contrast occurs primarily in leukocytes. IL-1β was detectable at very low concentrations in the patient urine samples; however, a significant increase after contrast administration could not be detected. Similarly, multiple other biomarkers including IL-6, lipocalin-2 (NGAL), MCP-1, EGF, and IL-1α, were not significantly increased in patient urine immediately after contrast administration (data not shown). Finally, none of the biomarkers were predictive of AKI within 7 days. In a preliminary analysis, the incidence of CI-AKI in this stable patient cohort was low and less than 10%, consistent with the multiple factors, aside from inflammation, needed to develop this clinical complication.

Figure 6. Contrast uptake by infiltrating LysM-GFP+ leukocytes. (A) LysM<sup>GFP<sup>lo/hi</sup></sup> mice were injected with CF568-labeled DTA and imaged with multiphoton intravital microscopy. Capillaries were labeled with Qtracker, and tubules are visualized by autofluorescence. Images are representative of 3 independent experiments. Scale bars: 50 μm. (B) Infiltrating LysM-GFP<sup>+</sup> leukocytes (blue) interacting directly with DTA-laden tubules (white) at 40 minutes (dashed red boxes). Images are representative of 3 independent experiments. Scale bars: 25 μm. (C) Flow cytometry characterization of contrast uptake in leukocytes isolated from mouse kidneys 1 hour after treatment with CF568-labeled DTA. Leukocytes were sorted using CD11b<sup>+</sup>, and CD45<sup>+</sup>, Ly6C<sup>+</sup>, Ly6G<sup>+</sup>, F4/80<sup>+</sup> populations were analyzed for DTA uptake. Images are representative of 3 independent experiments.
occurs. In combination with an inflammatory response, CI-AKI ensues. The finding of focal accumulation of contrast media in tubules sheds light mechanistically on the increased risk of CI-AKI in patients with volume depletion or reduced nephron number and CKD. These observations also explain the effectiveness of the only known therapeutic intervention for CI-AKI, prehydration with crystalloid solutions (28, 29).

Recent studies have demonstrated an essential role for resident renal phagocytes in regulating the immune response to circulating immune complexes (9, 10). While IL-1 and other proinflammatory cytokines were suggested to be important downstream effectors of renal inflammation regulated by these cells, the molecular pathways regulating IL-1 secretion were not identified (9). Our results further clarify the biology of resident renal phagocytes and infiltrating monocytes/macrophages, identifying the Nlrp3 inflammasome as a key innate sensor in these leukocytes. While resident renal phagocytes and infiltrating monocyte/macrophage populations were central in the innate immune response to contrast, neutrophils, on the other hand, while recruited to the kidney and contributing to injury, were not found to play a significant role in inflammasome activation. The mechanism of inflammasome activation by radiographic contrast agents is multifactorial but likely involves osmotic stress and reactive oxygen species induced directly by contrast, as well as indirect responses to DAMPs release from injured TECs (1, 30, 31). Together with prior studies by our group and others, these data establish a two-compartment model of Nlrp3 function in the kidney (11, 13, 16, 32). The canonical Nlrp inflammasome is centered primarily in resident renal phagocytes Nevertheless, these data provide evidence that contrast administration activates the inflammasome and tubular injury early in humans undergoing coronary angiography.

Discussion
In this study, we elucidate the molecular and cellular mechanisms that drive AKI induced by radiographic contrast media. The pathogenesis of CI-AKI requires interplay among the intrarenal immune system, the renal tubular epithelium, and leukocyte recruitment that includes (a) uptake of contrast into perivascular resident and recruited renal phagocytes, (b) Nlrp3 inflammasome activation and IL-1–dependent leukocyte recruitment, (c) tubular reabsorption of contrast via renal DPEP-1, and (d) contrast-induced tubular injury (Figure 12). Each event is necessary, and none alone is sufficient to injure the kidney, transcending the notion that toxic effects of contrast agents on TECs alone are sufficient to drive the pathogenesis of CI-AKI. While tubular cell uptake of contrast and subsequent toxicity are critical for leukocyte recruitment and CI-AKI, the renal immune response plays an important role.

The toxicity of contrast agents on TECs may be overestimated by in vitro studies due to multiple confounding variables. The i.v. administration of contrast media, which is sufficient under specific clinical circumstances to induce AKI, is disseminated and largely diluted before reaching the kidney. Our data show that in euolemic states, contrast is filtered and rapidly excreted in the urine, with very little tubular uptake. During volume depletion, however, contrast is reabsorbed and accumulates focally within 30–60 minutes in the tubules, where cellular toxicity likely then
and recruited monocytes/macrophages, while a noncanonical Nlrp3 exists in TECs to regulate apoptosis. Since contrast agents did not induce apoptosis in primary TECs, Nlrp3 function in CI-AKI is mainly canonical. Our data are consistent with the study by Linkermann and colleagues, who showed that neither apoptosis nor necroptosis plays a role in contrast-induced epithelial cell death (19). Our findings are also consistent with a recent study demonstrating a role for Nlrp3 in CI-AKI (33) but contradict the observation that the phenotype is due to Nlrp3-dependent regulation of epithelial cell apoptosis. Significant differences in methodology, such as the use of cell lines rather than primary cell cultures, likely explain these discrepant findings.

Using intravital microscopy we show monocyte/macrophage sampling of contrast transported from the urine via a direct interaction with tubular cells. This urinary immune surveillance was performed by recruited LysM-GFP+ monocytes/macrophages as opposed to CX3CR1+ resident renal phagocytes that took up contrast primarily from the vascular space. The factors involved in the monocyte/macrophage and tubular cell “synapse” require further study. The uptake of contrast by infiltrating monocytes/

Figure 8. Characterization of inflammasome activation in infiltrating proinflammatory monocytes in CI-AKI. LysM<sup>Cre/loxp</sup> and Nlrp3<sup>−/−</sup> LysM<sup>Cre/loxp</sup> mice were treated with vehicle or ioversol and assessed at various time points. (A) LysM-GFP<sup>−</sup>CD11b<sup>+</sup> leukocytes were isolated from vehicle- or ioversol-treated LysM<sup>Cre/loxp</sup> mice at 6 hours and analyzed for inflammasome activation (active caspase-1) in infiltrating monocytes and resident macrophages by flow cytometry using CX3CR1, Ly6C, F4/80, and CCR2. Images are representative of 3 independent experiments. (B) LysM-GFP<sup>−</sup>CD11b<sup>+</sup>CX<sup>3</sup>CR1<sup>+</sup> Ly6C<sup>+</sup> monocytes/macrophages were isolated from LysM<sup>Cre/loxp</sup> and Nlrp3<sup>−/−</sup> LysM<sup>Cre/loxp</sup> mice treated with vehicle or ioversol and analyzed at 6 hours or 3 days using CCR2 and F4/80. Images are representative of 3 independent experiments.
macrophages depended on the cell adhesion molecule ICAM-1. SR-A did not appear to play a role; however, other scavenger receptors may be involved. On the contrary, neutrophils did not take up measurable amounts of contrast in vivo, perhaps reflecting differential expression of cell surface receptors needed for this function compared with monocyte/macrophages. Therefore, the kidney possesses several mechanisms to monitor the vascular and urinary environments for potential pathogen-associated molecular patterns (PAMPs) and DAMPs. While it seems clear that resident renal phagocytes perform an important sentinel function to trigger immune responses in the kidney, our data suggest that urinary immune surveillance by recruited monocytes/macrophages may serve to amplify the inflammatory response via the uptake of DAMPs and the activation of innate immune pathways such as...
the Nlrp3 inflammasome. In a different context, urinary immune surveillance may also represent an important mechanism for antigen uptake and the development of adaptive immunity. Future investigation into the relationship between vascular and urinary immune surveillance and the role of luminal tubular receptors such as DPEP-1 in this process will only continue to increase the understanding of renal inflammation, kidney injury, and disease.

Finally, our studies identify several new therapeutic targets to prevent CI-AKI in humans. First, pilot data in our human CI-AKI cohort confirm the early activation of inflammasome-related pathways and inflammation in patients who receive contrast during coronary angiography. Targeting IL-1, the Nlrp3 inflammasome, or leukocyte recruitment may be useful as adjunct to current standard of care for the prevention of CI-AKI. Second, we identify renal DPEP-1 as the receptor for the tubular reabsorption of contrast. The DPEP-1 inhibitor cilastatin is currently used clinically to prevent tubular uptake and metabolism of the antibiotic imipenem (34) and would be immediately available as a single agent for therapeutic clinical trials in CI-AKI. Recently, a study by Hori et al. suggested that antibiotic nephrotoxicity and the beneficial effects of cilastatin were mediated by the megalin receptor in the proximal tubule (26). While this may contribute to tubular contrast uptake, our in vitro data clearly show a role for DPEP-1 in this process. Whether cilastatin also provides beneficial off-target effects in CI-AKI will require further study. While preventing tubular uptake of contrast with i.v. fluids is the key first step to interrupting the pathogenesis of CI-AKI, in patients who are unable to receive i.v. fluids, targeting inflammation or DPEP-1 becomes a feasible option.

Methods

Mouse studies

Nlrp3<sup>−/−</sup> (C57BL/6, The Jackson Laboratory), Nlrp3<sup>+/−</sup> (provided by J. Tschopp, University of Lausanne, Lausanne, Switzerland), LysM<sup>CreCre</sup> (provided by T. Graf, Centre for Genomic Regulation, Barcelona, Spain), CX<sub>C</sub>CRI<sup>−/−</sup> (The Jackson Laboratory), and CD11c-DTR<sup>CreCre</sup> (The Jackson Laboratory) mice were on a C57BL/6 background and housed under standard conditions. Nlrp3<sup>−/−</sup> LysM<sup>CreCre</sup> and Nlrp3<sup>+/−</sup> LysM<sup>CreCre</sup> littermates were generated by crossing LysM<sup>CreCre</sup> and Nlrp3<sup>−/−</sup> mice. Nlrp3<sup>−/−</sup> and Nlrp3<sup>+/−</sup> littermates were also generated and used in experiments. Mice were used between 8 and 12 weeks of age. For induction of CI-AKI, mice underwent water deprivation for 2 days prior to i.v. administration (5 ml/kg body weight) of ioversol (Optiray 320, Mallinckrodt Pharmaceuticals) or DTA (Sigma-Aldrich). For hydration studies, mice did not undergo water deprivation and were given 200 μl normal saline i.v. prior to contrast. Depletion studies in mice were performed using clodronate-liposomes (200 μl i.v., ClodronateLiposomes.com), PBS liposomes (200 μl i.v., ClodronateLiposomes.com), anti-Ly6G (200 μg i.p., BioXCell, catalog BE0075-1), anti-ICAM-1 (200 μg i.p., BioXCell, catalog BE0020-1), anti-IgG (200 μg i.p., BioXCell, catalog BE0086), D-4F peptide (21, 22) (20 μg i.p., CanPeptide), and Kineret (100 mg/kg i.p., Sobi). CD11c-DTR<sup>CreCre</sup> mice were depleted via diphtheria toxin (8 ng/kg body weight i.p.). Cilastatin (Tocris Bioscience) was administered at a dose of 25 mg/kg in 100 μl normal saline 30 minutes prior to contrast injection (control mice only received 100 μl saline). Urine was collected using metabolic cages. For chimeric studies, bone marrow cells were isolated from Nlrp3<sup>+/−</sup> and Nlrp3<sup>−/−</sup> mice and administered to clodronate-liposome-treated and irradiated recipients as described previously (14). Depletion of circulating and resident immune cells in the kidney was verified using intravital microscopy.

Cell culture

Marine TECs. TECs were isolated from kidneys harvested from mice between the ages of 8 and 12 weeks. Under sterile conditions, the kidney capsule and surrounding fatty tissue were removed from the kidney, and the renal cortex was removed. Renal cortical tissue was incubated in 1.5 mg/ml collagenase (Sigma-Aldrich) and incubated at 37°C for 1 hour. Tissue was washed through a 40-μm nylon cell strainer (BD Biosciences) and washed with HBSS (Gibco, Thermo Fisher Scientific). Cells were plated on collagen IV-coated (Sigma-Aldrich) culture dishes and grown in DMEM/F-12 (Gibco) containing 10% FBS, 125 ng/ml prostaglandin E1, 10 ng/ml EGF, 1.8 μg/ml l-thyroxine, 3.38 ng/ml hydrocortisone, 2.5 mg/ml insulin-transferrin-sodium selenite supplement, and 15 ng/ml murine EGF (Sigma-Aldrich) at 37°C. Cells were washed the next day and grown to confluence in K1 media at 37°C, 5% CO<sub>2</sub>, humidified incubator. Renal TECs isolated from Rip3<sup>−/−</sup> mice were prepared as above by Anthony M. Jevnikar of the University of Western Ontario (London, Ontario, Canada). All in vitro experiments were completed within two cell passages.

HPTCs and glomerular endothelial cells. Kidney tissues were obtained from non-diseased margins of human nephrectomies that were performed for medically indicated reasons. Kidney tissues were collected within 2 hours of surgery in HBSS supplemented with 5 mg/ml penicillin/streptomycin on ice. Following removal of the renal capsule, cortical tissue was carefully cut away and minced using aseptic techniques. After digestion in collagenase (1.5 mg/ml in HBSS) at 37°C for 60 minutes, samples were passed through serial filters from 200 to 45 μm to remove intact glomeruli and large cellular debris. Samples were then plated on plastic cell culture plates at 37°C for 90 minutes in K1 culture medium DMEM/F12 containing 10% FBS, 1% penicillin-streptomycin, 125 ng/ml prostaglandin E1, 1.8 μg/ml l-thyroxine, 3.38 ng/ml hydrocortisone, 2.5 mg/ml insulin-transferrin-sodium selenite supplement, and 10 ng/ml EGF (Sigma-Aldrich). HPTCs were collected and plated onto collagen IV-coated cell culture plates. To maintain the epithelial phenotype, HPTCs were used at fewer than 2 passages. For cell toxicity studies, nercosulfonamide (10 μM, Calbiochem), Necrostatin-1 (10 μM, Sigma-Aldrich), or Ferrostatin-1 (10 μM, Sigma-Aldrich) was applied to cells 30 minutes prior to contrast agents. Primary cultures of human glomerular endothelial cells (GECs; Cell Systems) were commercially obtained and cultured according to the manufacturer’s protocol.

Marine BMDMs. BMDMs were isolated from femurs and tibiae of mice aged 8–12 weeks. Bone marrow was isolated on ice and washed with HBSS twice. BMDMs were plated on culture dishes and grown in RPMI-1640 (Gibco) supplemented with L929 conditioned media and penicillin/streptomycin for 7 days before use in experiments. BMDMs were primed with 200 ng/ml Ultrapure LPS (Sigma-Aldrich) for 4 hours before treatments.

Marine renal pericyte isolation and culture. Pericytes were isolated from kidneys of mice aged 8–12 weeks as previously described (35). Briefly, pericytes were isolated using magnetic bead isolation (Mag-Cellact Ferrofluid, R&D Systems) and anti-PDGFRβ-positive (clone 28E1, Cell Signaling Technology) selection. Pericytes were grown on
Figure 10. Renal DPEP-1 mediates tubular uptake of contrast from the urine. (A and B) Contrast uptake (internalization) was imaged and quantified in human renal proximal TECs (HPTCs) using CF568-labeled DTA. PNGaseF was used to de-glycosylate DPEP-1 on HPTCs as a negative control. Scale bars: 10 μm. NT vs. CF568-ETA, ***P = 0.001, n = 9–14/group. ANOVA. (C) WT mice were treated with cilastatin prior to administration of CF568-ETA, and kidneys were imaged by multiphoton intravital microscopy over 40 minutes. Capillaries were labeled with Qtracker, and tubules are visualized by autofluorescence. Images are representative of 3 independent experiments. Scale bars: 100 μm. (D and E) Lys13HSL/GFP mice were treated with cilastatin (25 mg/kg) or vehicle control prior to administration of ioversol, and kidneys were imaged by multiphoton intravital microscopy. Scale bars: 100 μm. Inflammation was quantified by manual counting of stationary GFP+ leukocytes (saline vs. cilastatin, *P = 0.02, n = 3/group, 2-tailed Student’s t test). (F and G) WT C57BL/6J mice were treated with cilastatin or normal saline vehicle prior to ioversol administration. Urine output and serum creatinine as a measure of kidney function was determined on days 1 and 3 after contrast treatment (ref. values 0.04–0.08 mg/dl) (saline vs. cilastatin, creatinine day 3, **P = 0.02, n = 4/group, 2-tailed Student’s t test).

CRISPR/Cas9 NLRP3 gene editing

Nlrp3–/– THP-1 cells were produced using the lentivCRISPRv2 shuttle plasmid (Addgene plasmid 52961, provided by Feng Zhang, Broad Institute and Massachusetts Institute of Technology, Boston, Massachusetts, USA). The lentivCRISPRv2 included 3 expression cassettes, the Cas9 nuclease, puromycin resistance, and the guide RNA scaffold, into which a pair of annealed oligonucleotides complementary to bases 767–787 in the first exon of the Nlrp3 gene were cloned using BsmBI digestion sites. The following Nlr3 targeting oligonucleotides were synthesized: 5′-CACCGCTGCAAGCTGGCCAGGTACC-3′, 5′-AAACGTTACCTGGCCACGTACG-3′. Oligonucleotides were annealed by the addition of 0.1 mol of each to 0.5 μl polynucleotide kinase in 10× T4 ligation buffer (New England Biolabs) at 37°C for 30 minutes, 95°C for 5 minutes, followed by ramping down the temperature by 5°C/min to 25°C. The lentivCRISPRv2 plasmid was then digested with BsmBI and dephosphorylated with alkaline phosphatase for 30 minutes at 37°C, and the annealed oligonucleotides were ligated into the BsmBI-digested lentivCRISPRv2. HEK293T cells were transfected with the Nlrp3-targeting lentivCRISPRv2 construct, viral envelope plasmid pCMV-VSVG, and viral packing vector psPAX2. The virus-containing medium was collected every 12 hours and concentrated by ultracentrifugation at 50,000 rpm for 120 minutes. THP-1 cells were transduced with 5 μl concentrated viral particles and maintained at 37°C, 5% CO2 in complete RPMI containing 5 μg/ml puromycin for a total of 8 passages. To confirm the effectiveness of the CRISPR gene editing, genomic DNA was isolated from THP-1 cells. PCR for amplification of the target cleavage site was performed using the following primers: F: 5′-TCCGAGCGA-CAAGAAAACATT-3′, R: 5′-TGCGCTATCCCTTTGGCT-3′. PCR products were digested with KpnI. WT THP-1 cells showed a 564- and 241-bp fragment, whereas Nlrp3–/– cells showed an 805-bp band before and after KpnI digestion, indicating that Nlrp3–/– (CRISPR) cells had incorporated the appropriate mutation within the Nlrp3 gene. Nlrp3 protein expression was determined by immunoblotting as described below (Supplemental Figure 16).

Immunoblotting

Protein samples were separated by SDS-PAGE gels under reducing conditions. Proteins were transferred onto nitrocellulose membranes (GE Healthcare) and blocked for 1 hour with blocking solution before overnight incubation at 4°C with primary antibody. Blots were washed and incubated with appropriate secondary antibody conjugated to horseradish peroxidase at room temperature. Proteins were visualized with ECL Western blotting detection reagents (GE Healthcare) and digitally captured with a Chemidoc MP device (Bio-Rad). Denitrosity was performed using Image Lab software (Bio-Rad) and normalized as indicated. Antibodies used were as follows: caspase-8 (clone 1C12, Cell Signaling Technology), caspase-3 (Cell Signaling Technology, catalog 9662), PAR (Cell Signaling Technology, catalog 9542), MLKL (clone D6H3V, Cell Signaling Technology), RIPK3 (clone E1ZID, Cell Signaling Technology), caspase-1 (Santa Cruz Bio-technology Inc., catalog SC-622 targeting N-terminal CARD domain), Nlrp3 (clone CRYO-2, Adipogen), ASC (Adipogen, catalog AL177), IL-1β (pro-IL1β; clone 3A6; cleaved-IL1β; clone D3AZ3, Cell Signaling Technology), GAPDH (Abcam, catalog ab9485), and β-tubulin (Sigma-Aldrich, catalog T0198).

ELISA

THP-1 cells were differentiated with PMA, and BMDMs were primed with ultrapure LPS for 4 hours before treatment. Nigericin (50 μM, Tocris Bioscience) or ATP (5 mM, Sigma-Aldrich) treatment was used as positive controls. Cell supernatants were used to detect IL-1β cytokine secretion by ELISA (BD Biosciences) as per the manufacturer’s instructions.

MTT assay

TECs were assessed for cell viability using MTT assay as per the manufacturer’s instructions (Invitrogen, Thermo Fisher Scientific). TECs were grown to monolayer and treated with various reagents for 24 hours in serum-free media. Cells were incubated with MTT (12 mM) for 4 hours at 37°C. Viable cells converted MTT to formazan, which was solubilized by DMSO before quantification by spectrophotometry at 540 nm. Cell viability was calculated for each treatment relative to untreated cells.

gelatin-coated culture dishes in pericyte medium. Cells were characterized by the positive marker PDGFRβ (clone C82A3, Cell Signaling Technology) and negative marker E-cadherin (clone G101B1, BD Biosciences). Renal pericytes (NG2+ cells) were also characterized in vivo via intravitral microscopy of Tg(Cspg4-DsRed.T1)1AkikJ mice (The Jackson Laboratory). THP-1 cell line. The human myelogenous leukemia THP-1 cell line was purchased from ATCC. THP-1 cells were cultured in RPMI-1640 supplemented with 10% FBS, 1% penicillin/streptomycin, 0.05 mM β-mercaptoethanol, and 1 mM sodium pyruvate. Cells were maintained in suspension in a 37°C, 5% CO2, humidified incubator. Cells were differentiated with 100 nM PMA (Sigma-Aldrich) for 24 hours prior to experiments.

Generation of necrotic DAMPs. DAMPs were prepared from HPTCs and THP-1 cells via treatment with hydrogen peroxide (500 mM, 3 hours), nigericin (50 μM, 30 minutes), or ioversol (3 hours) before replacement with serum-free media for 24 hours to generate DAMPs. Supernatants were collected from treated cells and added to new THP-1 cultures for 6 hours. Necrotic DNA was generated via filtration of necrotic cell debris by a QIAshredder homogenizer (QIAGEN).
Figure 11. Inflammasome-related biomarkers are detected in human urine following contrast administration. (A) Urinary IL-18 and (B) KIM-1 before and less than 24 hours after coronary angiogram as determined by Meso Scale Discovery assay. Data points normalized to urine creatinine are shown (IL-18 before vs. after, P = 0.005, n = 42/group; KIM-1 before vs. after, P = 0.03, n = 42/group, Wilcoxon’s signed-rank test). (C) Caspase-1 immunoblotting from urine pellets in 2 healthy control individuals and 8 patients before and less than 24 hours after coronary angiogram. Nigericin-treated THP-1 macrophages were used as a positive control. Arrow indicates cleaved caspase-1 N-terminal CARD domain. (D) Caspase-1 immunoblotting from urine pellets in 9 patients before and less than 24 hours after coronary angiogram, with corresponding urine leukocyte score. (E) Quantification of caspase-1 expression versus leukocyte score in 17 patient urine samples before and less than 24 hours after coronary angiogram (caspase-1 densitometry normalized to urine creatinine per urine leukocyte score, 0 vs. 1: *P = 0.011, 0 vs. 2: ***P = 0.0001, n = 21, 7, and 6/group, ANOVA).

Live cell imaging

Cell death assay. TECs were grown to monolayer and treated with various reagents for 24 hours in color-free, serum-free media in the presence of propidium iodide (BD Biosciences) to label necrotic cells. TECs were imaged hourly for 24 hours using an automated fluorescence microscope (IncuCyte, Essen BioScience) in a 37°C, 5% CO₂ humidified incubator. Necrotic cell death was calculated by automated software (IncuCyte Zoom, Essen BioScience) as indicated by propidium iodide-positive cells.

Lipid peroxidation assay. TECs were grown to monolayer and treated with various reagents for 24 hours in color-free, serum-free media. Cumene hydroperoxide (100 µM, Sigma-Aldrich) was used as a positive control for lipid peroxidation in TECs. Lipid peroxidation was measured using an Image-iT Lipid Peroxidation Kit (Life Technologies), which emits fluorescence in the presence of oxidation. TECs were imaged hourly for 24 hours using an automated fluorescence microscope (IncuCyte) in a 37°C, 5% CO₂ humidified incubator. Peroxidation was calculated by automated software (IncuCyte Zoom).
hours, cells were treated with CF568-labeled DTA for 30 minutes, and extracellular DTA was washed away before labeling with anti-DPEP-1 antibody (Proteintech, catalog 12222-1-AP). Similarly, HPTCs were also treated with CF568-labeled DTA. As a negative control, PNGaseF (New England BioLabs) was used to de-glycosylate DPEP-1, which alters its apical targeting and enzymatic activity (27). Image acquisition of Z-stacks (15-μm stack, 1.5-μm steps) was done using a Nikon AIR MP+ confocal microscope. Contrast uptake in cells was quantified using ImageJ software (NIH).

Real-time PCR

Murine kidney tissue was homogenized and total RNA was isolated using Qiashredder and RNeasy Mini Kit (QIAGEN) as per the manufacturer’s instructions. cDNA was generated using M-MLV reverse transcriptase (Invitrogen) as per the manufacturer’s instructions. The sequences for human KIM-1 primers and probes are as follows: F: 5′-CTGGCTATACGCCATACAATCT-3′, R: 5′-GCGTTCTGCAAAGCTTCAATC-3′, probe FAM-5′-CTCTAAAGCGTGTTGC-3′-MB. The 18S rRNA FAM/MGB probe was used as endogenous control. Real-time PCR reactions were made using Tagman Universal PCR Mastermix (Bio-Rad), primers (900 nM), probe (250 nM), and cDNA template. Amplification was performed using the 7900HT Fast Real-Time PCR System (Bio-Rad).

Immunofluorescence microscopy of fixed samples

In vitro. THP-1 cells were differentiated with PMA on coverslips and treated with various reagents. Cells were incubated with FAM-YVAD-fmk (FLICA–capsase-1) (ImmunoChemistry Technologies) for 1 hour before fixation with 4% paraformaldehyde. Incubation with NH$_2$Cl (50 μM) was used to quench autofluorescence before permeabilization with 0.1% Triton X-100. Cells were blocked in 3% BSA before incubation with primary antibodies overnight at 4°C. Samples were then incubated with anti-human ASC (clone AL177, Adipogen), and cells were washed in PBS before incubation in secondary fluorescent antibody. Coverslips were mounted onto slides in ProLong Gold antifade (Invitrogen) containing DAPI. Images were acquired with a confocal fluorescence microscope (Olympus IX-70) with Fluoview 1000 software (Olympus).

In vivo. Murine kidneys were fixed in 10% neutral-buffered formalin and paraffinized before being mounted onto slides. Tissue sections were deparaffinized, blocked, and labeled with the following antibodies: anti–mouse KIM-1 (R&D Systems, catalog MAB31817), fluorescein-labeled *Lotus tetragonolobus* lectin (LTL, Vector Laboratories), anti-E-cadherin (clone G10181, BD Biosciences), or anti-F4/80 (clone CL:A3-1, Abcam). Images were acquired with a confocal fluorescence microscope (Olympus IX-70) with Fluoview 1000 software. Quantification of F4/80 labeling was done using ImageJ software.

Flow cytometry

Murine kidney tissue was isolated from mice after perfusion via saline injection into the heart. Kidney capsule and fat were removed before incubation of whole tissue in 2 mg/ml collagenase at 37°C for 30 minutes. Tissue homogenate was then passed through a 40-μm nylon cell strainer and washed in HBSS. Cell pellet was incubated in ACK lysis buffer (Gibco) for 3 minutes to remove red blood cells and washed in HBSS. Viable cells were isolated using a density gradient by mixing cells with Percoll (GE Healthcare) and centrifuging at 800 g for 25 minutes. Cells were washed in PBS and labeled with the following antibodies: Pacific Blue–conjugated anti-Ly6C (clone HKL1.4, BioLegend), PE-conjugated anti-Ly6G (clone 1A8, BioLegend), PE/Cy5-conjugated anti-F4/80 (clone BM8, BioLegend), eFluor780-conjugated anti-CD11b (clone M1/70, eBioscience), APC/Cy7-conjugated anti-CD11c (clone N418, BioLegend), FITC-conjugated CD45 (clone 30-F11, eBioscience), Pacific Blue–conjugated 1-A/1-E (clone M5/14.15.2, BioLegend), PE-conjugated CD192 (CCR2) (clone SA203G11, BioLegend), Brilliant Violet 421–conjugated anti-CX3CR1 (clone SA011F11, BioLegend), and FLICA caspase-1 (FAM-YVAD-fmk, Immunochemistry Technologies). Cells were resuspended in FACS buffer before analysis by a BD LSRII flow cytometer (BD Biosciences) or Attune (Life Technologies) and FlowJo software.

Cell sorting of resident renal phagocytes. Resident renal phagocytes (CX3CR1$^{+}$ cells) were isolated from CX3CR1$^{GFP/−}$ mice using fluorescence cell sorting. The phenotype of CX3CR1$^{+}$ cells was confirmed using intravital microscopy. Murine kidney tissue was isolated from mice after perfusion via saline injection into the heart. Kidney capsule and fat were removed before incubation of whole tissue in 2 mg/ml collagenase at 37°C for 30 minutes. Tissue homogenate was then passed through a 40-μm nylon cell strainer and washed in HBSS. Viable cells were isolated using a density gradient by mixing cells with Percoll (GE Healthcare) and centrifuging at 800 g for 25 minutes. Cell viability was determined using SYTOX (Thermo Fisher Scientific) labeling. Cells were analyzed and sorted using a BD FACSARIA III (BD Biosciences).

Kidney multiphoton intravital microscopy and quantification

Mice were anesthetized using ketamine (100 mg/kg) and xylazine (10 mg/kg) supplemented with isoflurane before catheterization via tail vein for further administration of additional anaesthetic or labeling reagents. The kidney was exteriorized using a lateral incision and extended over the heated imaging platform. Imaging was done using a Leica multiphoton confocal microscope equipped with ×25 water or ×63 oil objective lens and Mai Tai pulsed infrared laser (Leica). Experiments were done at 1,000 nM excitation. Predefined settings for laser power and detector gain were used for all experiments. Time lapse imaging was acquired at 0.5 seconds per frame. Z-stacks were taken at 20-μm optical sections with 2-μm steps. Qtracker 655 (Thermo Fisher Scientific) was used in all mice to visualize capillaries, and SYTOX was used to label necrotic cells in vivo. Fluorescent-conjugated DTA (Sigma-Aldrich) was synthesized using 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride crosslinked (EDC, Sigma-Aldrich) DTA with CF568-amine (Sigma-Aldrich). CF568 alone or CF568 conjugated to acetic acid was used as control. All acquisition and image processing was done with native LAS X software (Leica). Adherent LysM-GFP$^{+}$ and CX3CR1-GFP$^{+}$ cells were manually counted in each field based on their fixed position over the course of 2 minutes. Necrotic cells were quantified by measuring SYTOX-positive cells as a percentage of total cells (injury index) by ImageJ. A minimum of 3 fields were acquired and analyzed per mouse for all quantification. Renal dendritic cell activity in CX3CR1$^{GFP/−}$ mice was determined as previously described (36).

Creatinine assays

Renal function was determined in mouse serum using an enzymatic serum creatinine assay performed by Calgary Laboratory Services.
Urinary creatinine in human specimens was measured using a Creatinine Companion Kit (Exocell) as per the manufacturer’s instructions.

**Human contrast-induced acute kidney injury study**

Human urine specimens were obtained from an ongoing prospective biomarker study at the University of Calgary. Pre- and post-angiography urine specimens were chosen from 42 inpatients who underwent elective or urgent coronary angiogram procedures between December 2015 and May 2017 at the Foothills Medical Centre in Calgary, Alberta, Canada (Supplemental Table 1). Patients were eligible to participate in the study if they had evidence of kidney impairment (eGFR <60 ml/min/1.73 m²) and were willing to provide mid-stream urine samples. Individuals with prior renal transplantation, evidence of AKI in the previous 30 days (>26 μmol/l increase in serum creatinine in last 30 days), unable to produce a urine sample (ileal conduit or <100 cc/d urine output), or residing outside of Alberta were not eligible to participate. Approximately 20–50 ml urine was collected in a 90-ml container prior to coronary angiogram (baseline) and between 12 and 24 hours after coronary angiogram. Urine samples were set on ice and transported to the Biobank for the Molecular Classification of Kidney Disease (BMCKD, Snyder Institute for Chronic Diseases, Calgary, Alberta, Canada) within 1 hour. Specimens were immediately subjected to dipstick analysis (Chemstrip 10; Roche Diagnostics) and promptly centrifuged at 1,500 g for 10 minutes at 4°C. The urine pellet as well as aliquots of the urine supernatant were placed in Micronic cryovials and stored at −80°C. Caspase-1 immunoblotting was performed on urinary pellet fractions. Meso Scale Discovery assays for KIM-1 and IL-18 were performed on urine supernatants as per the manufacturer’s protocol.

**Statistics**

Data are shown as mean ± SEM. All experiments were performed at least 3 independent times. GraphPad Prism software version 7.03 was used to perform all statistical analyses. Results were analyzed for statistical variance using unpaired Student’s t test (2-tailed) or ANOVA and promptly centrifuged at 1,500 g for 10 minutes at 4°C. The urine pellet as well as aliquots of the urine supernatant were placed in Micronic cryovials and stored at −80°C. Caspase-1 immunoblotting was performed on urinary pellet fractions. Meso Scale Discovery assays for KIM-1 and IL-18 were performed on urine supernatants as per the manufacturer’s protocol.

Human contrast-induced acute kidney injury study

Human urine specimens were obtained from an ongoing prospective biomarker study at the University of Calgary. Pre- and post-angiography urine specimens were chosen from 42 inpatients who underwent elective or urgent coronary angiogram procedures between December 2015 and May 2017 at the Foothills Medical Centre in Calgary, Alberta, Canada (Supplemental Table 1). Patients were eligible to participate in the study if they had evidence of kidney impairment (eGFR <60 ml/min/1.73 m²) and were willing to provide mid-stream urine samples. Individuals with prior renal transplantation, evidence of AKI in the previous 30 days (>26 μmol/l increase in serum creatinine in last 30 days), unable to produce a urine sample (ileal conduit or <100 cc/d urine output), or residing outside of Alberta were not eligible to participate. Approximately 20–50 ml urine was collected in a 90-ml container prior to coronary angiogram (baseline) and between 12 and 24 hours after coronary angiogram. Urine samples were set on ice and transported to the Biobank for the Molecular Classification of Kidney Disease (BMCKD, Snyder Institute for Chronic Diseases, Calgary, Alberta, Canada) within 1 hour. Specimens were immediately subjected to dipstick analysis (Chemstrip 10; Roche Diagnostics) and promptly centrifuged at 1,500 g for 10 minutes at 4°C. The urine pellet as well as aliquots of the urine supernatant were placed in Micronic cryovials and stored at −80°C. Caspase-1 immunoblotting was performed on urinary pellet fractions. Meso Scale Discovery assays for KIM-1 and IL-18 were performed on urine supernatants as per the manufacturer’s protocol.

**Statistics**

Data are shown as mean ± SEM. All experiments were performed at least 3 independent times. GraphPad Prism software version 7.03 was used to perform all statistical analyses. Results were analyzed for statistical variance using unpaired Student’s t test (2-tailed) or ANOVA and promptly centrifuged at 1,500 g for 10 minutes at 4°C. The urine pellet as well as aliquots of the urine supernatant were placed in Micronic cryovials and stored at −80°C. Caspase-1 immunoblotting was performed on urinary pellet fractions. Meso Scale Discovery assays for KIM-1 and IL-18 were performed on urine supernatants as per the manufacturer’s protocol.

**Study approval**

**Animal studies.** All animal studies were reviewed and approved by the Animal Care Committee at the University of Calgary.

**Human studies.** All human studies were reviewed and approved by the Conjoint Health Research Ethics Board at the University of Calgary and Alberta Health Services (Calgary, Alberta, Canada). Patients provided written informed consent to participate in the CI-AKI study. HPTC isolation involved the secondary use of anonymized nephrectomy samples slated for disposal and therefore did not require patient consent.

**Author contributions**

AL performed the majority of experiments and wrote the manuscript. HJC, JMP, AUL, TK, SRC, JC, CFS, VN, BGJS, MCN, SLS, and PLB performed experiments, contributed data, and reviewed the manuscript. HB reviewed renal pathology. AMJ provided mouse strains, reagents, and expertise for necroptosis experiments and reviewed the manuscript. MJH provided expertise, analyzed CX3CR1 data, reviewed the manuscript, and supervised SLS. DLS provided expertise and DPEP-1 reagents, reviewed the manuscript, and supervised SRC. MTJ led the clinical CI-AKI study and provided patient data. JAM provided expertise, reviewed the manuscript, and supervised AUL. PK provided expertise, reporter mouse strains, and reagents; reviewed the manuscript; and supervised BGJS. CNJ provided intravital microscopy equipment and expertise, analyzed data, reviewed the manuscript, and supervised VN. DAM supervised and managed the entire project.

**Acknowledgments**

This work was supported by Operating and Foundation grants from the Canadian Institutes of Health Research (CIHR). Research was also supported by the Canadian National Trans-
plantation Research Program (CNTRP) and the CIHR Inflammation in Chronic Disease Signature Initiative. DAM holds a Tier II Canada Research Chair. JAM was the holder of a Marie Skłodowska-Curie International Incoming Fellowship from the European Commission. MTJ is supported by a CIHR New Investigator Award. AL holds a Postdoctoral Scholarship Award from Alberta Innovates Health Solutions (AIHS). JMP and AL were also supported by Beverley Phillips Trainee Awards from the Snyder Institute for Chronic Disease, University of Calgary. The authors acknowledge May Ho and Stephen Robbins for their critical review of the manuscript, as well as Sharon A. Clark, Björn Petri, Kuo-Chieh Liao, and Adom Bondzi-Simpson for technical support. Infrastructure and technical support was provided by the Live Cell Imaging Facility, Mouse Phenomics Resource Laboratory, and the BMCKD at the Snyder Institute for Chronic Diseases.

Address correspondence to: Daniel Muruve, University of Calgary, 3280 Hospital Dr. NW, Calgary, AB, T2N 4Z6, Canada. Phone: 403.220.2418; Email: dmuruve@ucalgary.ca.